Anti-leukemic Activity of AIU2008 in FLT3-ITD-positive Acute Myeloid Leukemia
- 30 January 2021
- journal article
- research article
- Published by Anticancer Research USA Inc. in Anticancer Research
- Vol. 41 (2), 731-737
- https://doi.org/10.21873/anticanres.14824
Abstract
Background/Aim: FMS-like tyrosine kinase 3 (FLT3) is a class III receptor tyrosine kinase involved in signal transduction underlying survival, proliferation, and differentiation of hematopoietic cells. An internal tandem duplication (ITD) in FLT3 in the juxtamembrane domain is a common mutation causing human acute myeloid leukemia (AML) and activates constitutive signaling. Materials and Methods: We evaluated the novel FLT3 inhibitor 5-(4-fluorophenyl)-N-(naphthalen-1-yl)oxazol-2-amine (AIU2008) for the treatment of AML. Results: AIU2008 was designed by modifying FLT3 inhibitor 7c, and showed improved anti-leukemic efficacy in FLT3-ITD–positive AML cells. Specifically, AIU2008 inhibited cell growth and apoptotic death. In addition, AIU2008 down-regulated DNA repair genes involved in homologous recombination and non-homologous end joining. It contributed to the synergistic inhibition of AML cell growth in combination treatment with PARP inhibitors. Conclusion: AIU2008 is a promising FLT3 targeting agent, and may be used in combination with PARP inhibitors for the treatment of AML.Keywords
This publication has 21 references indexed in Scilit:
- JAK/STAT signaling in hematological malignanciesOncogene, 2012
- Synthetic lethality of PARP inhibition in cancers lackingBRCA1andBRCA2mutationsCell Cycle, 2011
- High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemiaBlood, 2011
- Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease stateLeukemia & Lymphoma, 2011
- Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AMLBlood, 2008
- DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412Leukemia, 2006
- BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cellsDNA Repair, 2006
- BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species–dependent DNA double-strand breaksBlood, 2004
- The roles of FLT3 in hematopoiesis and leukemiaBlood, 2002
- Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemiaLeukemia, 1997